{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:21:54Z","timestamp":1770333714111,"version":"3.49.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The nucleoporin gene NUP98 is fused to several genes including HOXD13 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia, and chronic myeloid leukemia, blast crisis. Genetically engineered mice that express a NUP98-HOXD13 (NHD13) transgene (Tg) display the phenotypic features of MDS, including cytopenias, bone marrow dysplasia, and transformation to acute leukemia. Here we show that short-term treatment with the p53 inhibitor Pifithrin-\u03b1 partially and transiently rescued the myeloid and lymphoid abnormalities found in NHD13+ Tg mice, with no improvement in the anemia, while the genetic deletion of 2 alleles of p53 rescued both the myeloid progenitor cell and long-term hematopoietic stem cell compartments. Nonetheless, loss of one or both alleles of p53 did not rescue the MDS phenotype, but instead exacerbated the MDS phenotype and accelerated the development of acute myeloid leukemia. Our studies suggest that while targeting p53 may transiently improve hematopoiesis in MDS, over the long-term, it has detrimental effects, raising caution about abrogating its function to treat the cytopenias that accompany this disease.<\/jats:p>","DOI":"10.1182\/blood-2012-01-405332","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T04:12:24Z","timestamp":1346127144000},"page":"3089-3097","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13\u2013driven mouse model"],"prefix":"10.1182","volume":"120","author":[{"given":"Haiming","family":"Xu","sequence":"first","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Menendez","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[{"name":"Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narae","family":"Bae","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Aplan","sequence":"additional","affiliation":[{"name":"Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"G\u00f6hring","sequence":"additional","affiliation":[{"name":"Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony R.","family":"Deblasio","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Nimer","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"University of Miami Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019111808394417100_B1","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","article-title":"Myelodysplastic syndromes.","volume":"111","author":"Nimer","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111808394417100_B2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2019111808394417100_B3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2004-12-4794","article-title":"NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.","volume":"106","author":"Lin","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111808394417100_B4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/1042819031000067620","article-title":"Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.","volume":"44","author":"Horiike","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111808394417100_B5","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood.V85.8.2189.bloodjournal8582189","article-title":"TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities.","volume":"85","author":"Kaneko","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2019111808394417100_B6","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V81.11.3022.3022","article-title":"Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.","volume":"81","author":"Sugimoto","year":"1993","journal-title":"Blood"},{"issue":"12","key":"2019111808394417100_B7","first-page":"1302","article-title":"P53 mutations in myelodysplastic syndromes.","volume":"6","author":"Ludwig","year":"1992","journal-title":"Leukemia"},{"issue":"15","key":"2019111808394417100_B8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression.","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7176","key":"2019111808394417100_B9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.","volume":"17","author":"Ebert","year":"2008","journal-title":"Nature"},{"issue":"1","key":"2019111808394417100_B10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2063","article-title":"A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.","volume":"16","author":"Barlow","year":"2010","journal-title":"Nat Med"},{"issue":"9","key":"2019111808394417100_B11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2010-07-295238","article-title":"Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.","volume":"117","author":"Dutt","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111808394417100_B12","first-page":"4269","article-title":"NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.","volume":"58","author":"Raza-Egilmez","year":"1998","journal-title":"Cancer Res"},{"issue":"11","key":"2019111808394417100_B13","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1182\/blood-2002-08-2484","article-title":"Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1.","volume":"101","author":"Pineault","year":"2003","journal-title":"Blood"},{"issue":"13","key":"2019111808394417100_B14","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1182\/blood-2004-01-0103","article-title":"Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.","volume":"15","author":"Chen","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111808394417100_B15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2005.05555.x","article-title":"CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.","volume":"130","author":"Heinrichs","year":"2005","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111808394417100_B16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self-renewal versus differentiation.","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"16","key":"2019111808394417100_B17","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/blood-2009-10-178129","article-title":"Ribosomopathies: human disorders of ribosome dysfunction.","volume":"115","author":"Narla","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111808394417100_B18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/ng.188","article-title":"Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects.","volume":"40","author":"McGowan","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"2019111808394417100_B19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ncb1858","article-title":"Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction.","volume":"11","author":"Fumagalli","year":"2009","journal-title":"Nat Cell Biol"},{"issue":"5434","key":"2019111808394417100_B20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.","volume":"285","author":"Komarov","year":"1999","journal-title":"Science"},{"issue":"24","key":"2019111808394417100_B21","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1523\/JNEUROSCI.0184-08.2008","article-title":"Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination.","volume":"28","author":"Li","year":"2008","journal-title":"J Neurosci"},{"issue":"6","key":"2019111808394417100_B22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0301-472X(03)00072-9","article-title":"Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice.","volume":"31","author":"TeKippe","year":"2003","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111808394417100_B23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.exphem.2008.04.012","article-title":"Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice.","volume":"36","author":"Chen","year":"2008","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111808394417100_B24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2006-03-010413","article-title":"The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging.","volume":"109","author":"Dumble","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111808394417100_B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.stem.2008.11.006","article-title":"p53 regulates hematopoietic stem cell quiescence.","volume":"4","author":"Liu","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2019111808394417100_B26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V100.1.238","article-title":"Hematopathology Subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.","volume":"100","author":"Kogan","year":"2002","journal-title":"Blood"},{"issue":"25","key":"2019111808394417100_B27","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2008-12-192054","article-title":"Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential.","volume":"18","author":"Kent","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111808394417100_B28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.stem.2010.02.002","article-title":"Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1.","volume":"5","author":"Challen","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"6","key":"2019111808394417100_B29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1084\/jem.20091318","article-title":"Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment.","volume":"207","author":"Morita","year":"2010","journal-title":"J Exp Med"},{"issue":"12","key":"2019111808394417100_B30","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1073\/pnas.1000834107","article-title":"Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion.","volume":"23","author":"Beerman","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111808394417100_B31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood.V78.7.1652.1652","article-title":"p53 gene mutations in acute myeloid leukemia with 17p monosomy.","volume":"78","author":"Fenaux","year":"1991","journal-title":"Blood"},{"issue":"12","key":"2019111808394417100_B32","first-page":"2243","article-title":"Mutations in the p53 gene in myelodysplastic syndromes.","volume":"6","author":"Jonveaux","year":"1991","journal-title":"Oncogene"},{"issue":"5","key":"2019111808394417100_B33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation.","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"7192","key":"2019111808394417100_B34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature06869","article-title":"Long-term haematopoietic reconstitution by Trp53\u2212\/\u2212p16Ink4a\u2212\/\u2212p19Arf\u2212\/\u2212 multipotent progenitors.","volume":"8","author":"Akala","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2019111808394417100_B35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cell.2009.06.048","article-title":"The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.","volume":"18","author":"Cicalese","year":"2009","journal-title":"Cell"},{"issue":"13","key":"2019111808394417100_B36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1101\/gad.1940710","article-title":"p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.","volume":"24","author":"Zhao","year":"2010","journal-title":"Genes Dev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/15\/3089\/1359354\/zh804112003089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/15\/3089\/1359354\/zh804112003089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:08:27Z","timestamp":1574086107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/15\/3089\/30638\/Loss-of-p53-accelerates-the-complications-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,11]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,10,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-405332","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,11]]}}}